| [1]Mascarenhas L. Long acting methods of contraception. BMJ. 1994;308(6935):991-992.[2]Darney PD. Hormonal implants: contraception for a new century. Am J Obstet Gynecol. 1994;170(5 Pt 2):1536-1543.[3]Sivin I, Alvarez F, Mishell DR Jr, et al. Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic. Contraception. 1998;58(5):275-282.[4]Segal SJ, Croxatto HB. Single administration of hormones for long-term control of reproductive function. Washington DC:Proceedings of the 23rd Meeting of the American Fertility Society, 1967.[5]Segal SJ. Contraceptive subdermal implants. In: Mishell DR Jr, edits. Advances in Fertility Research. New York: Raven Press, 1982:117-127.[6]黄婷,曾佳,相琳,等. 烯诺孕酮制剂研究进展[J]. 中国新药杂志, 2015, 24(4):409-414.[7]Feldblum PJ, Hanitriniaina O, Lendvay A, et al. Performance of Sino-implant (II) in routine service delivery in Madagascar. Contraception. 2013;88(1):103-108.[8]Trussell J. The Essentials of Contraception: Efficacy, Safety, and Personal considerations. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D, edits, Contraceptive Technology. New York: Ardent Media, 2007: 343-349.[9]WHO Guidelines Approved by the Guidelines Review Committee.Medical Eligibility Criteria for Contraceptive Use.5th edition. Geneva: World Health Organization, 2015.[10]郭延玲,傅正英.可复性输卵管避孕材料应用进展[J].医疗卫生装备,2011,32(6):85-87.[11]杨丹.第三代口服避孕药的药代动力学和对代谢的影响[J]. 实用妇产科杂志, 2001, 17(6): 32-325.[12]张翀,杨丹,孟舒,等. 生物可降解高分子材料在避孕领域中的应用进展[J].塑料,2011,40 (1):49-51.[13]汤谷平, 陈启琪. 可生物降解的高分子材料在控释出体避孕药中的应用[J]. 生殖与避孕, 1997,17(5):259-261.[14]钱翠凤,黄紫蓉. 皮下埋植避孕剂的研究进展[J]. 国际生殖健康/计划生育杂志, 2013,32(2):107-110.[15]Townsend S. Norplant: safe and highly effective. Netw Res Triangle Park N C. 1990;11(4):6-8.[16]Trussell J, Hatcher RA, Cates W Jr, et al. Contraceptive failure in the United States: an update. Stud Fam Plann. 1990;21(1):51-54.[17]Chetri M, Bhatta A, Amatya RN, et al. Five-year evaluation of safety, efficacy and acceptability of Norplant implants in Nepal. Adv Contracept. 1996;12(3):187-199.[18]Sivin I, Mishell DR Jr, Darney P, et al. Levonorgestrel capsule implants in the United States: a 5-year study. Obstet Gynecol. 1998;92(3):337-344.[19]Gu S, Sivin I, Du M, et al. Effectiveness of Norplant implants through seven years: a large-scale study in China. Contraception. 1995;52(2):99-103.[20]Sivin I. International experience with NORPLANT and NORPLANT-2 contraceptives. Stud Fam Plann. 1988;19(2):81-94.[21]Diaz S, Pavez M, Miranda P, et al. A five-year clinical trial of levonorgestrel silastic implants (Norplant TM). Contraception. 1982;25(5):447-456.[22]张倩,姚小东,宁美英,等. 女性避孕药物制剂的研究进展[J]. 中国计划生育学杂志,2015, 23(7):501-504.[23]Croxatto HB, Díaz S, Pavez M, et al. Clearance of levonorgestrel from the circulation following removal of NORPLANT subdermal implants. Contraception. 1988;38(5):509-523.[24]李明英. 放置皮下埋植剂238例避孕效果[J]. 中国生育健康杂志, 2008, 19(2): 121,124．[25]Tu P, Qiu S, Fang H, et al. Acceptance, efficacy, and side effects of Norplant implants in four counties in north China. Stud Fam Plann. 1997;28(2):122-131.[26]Díaz S, Herreros C, Juez G, et al. Fertility regulation in nursing women: VII. Influence of NORPLANT levonorgestrel implants upon lactation and infant growth.Contraception. 1985;32(1):53-74.[27]Shaaban MM, Salem HT, Abdullah KA. Influence of levonorgestrel contraceptive implants, NORPLANT, initiated early postpartum upon lactation and infant growth. Contraception. 1985;32(6):623-635.[28]The Piopulation Councile. Norplant-a summary of scientific data. New York: The Population Council, 1990: 1-26.[29]Darney PD, Klaisle CM, Tanner S. Sustained-release contraceptives. Current Problems in Obstetrics Gynecology & Fertility. 1990; 13(3): 95-125. [30]杜娟,雷贞武. 单纯孕激素长效避孕剂安全性研究进展[J]. 实用妇产科杂志,2014,30(7):485-488.[31]雷贞武,周静. 皮下埋植避孕剂出血不良反应及安全性的研究进展[J]. 国际生殖健康/计划生育杂志,2011,30(6):425-428.[32]高瞰秀,聂垚. 基于各类型材料的宫内节育器、皮下避孕埋植剂及输卵管节育器[J].中国组织工程研究,2015,19(52):8503-8508.[33]Jackanicz TM, Nash HA, Wise DL, et al. Polylactic acid as a biodegradable carrier for contraceptive steroids. Contraception. 1973; 8(3): 227-234.[34]Beck LR, Cowsar DR, Lewis DH, et al. New long-acting injectable microcapsule contraceptive system. Am J Obstet Gynecol. 1979;135(3):419-426.[35]Hahn DW, Mcguire JL, Cohn RM, et al. Development of microencapsulated norgestimate as a long-acting contraceptive. In: Zatuchni GL, edits, Long-Acting Contraceptive Delivery Systems. Philadelphia: Harpen and Row, 1984: 96-112.[36]Sun H, Mei L, Song C, et al. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials. 2006;27(9):1735-1740.[37]Pitt CG, Chasalow FI, Hibionada YM, et al. Aliphatic polyesters. I. The degradation of poly(ε-caprolactone) in vivo. Journal of Applied Polymer Science. 1981; 26(11): 3779-3787.[38]武莉,孙洪范,杨菁,等. 医用聚已内酯长期毒性动物实验研究[J]. 天津医药, 2008, 36(2): 126-129.[39]Sinha VR, Bansal K, Kaushik R, et al. Poly-epsilon- caprolactone microspheres and nanospheres: an overview. Int J Pharm. 2004;278(1):1-23.[40]Baker R. Controlled release of biologically active agents. Menlo Park, California: Membrane Technology and Research Inc, 1984: 89.[41]Pitt CG, Gratzl MM, Jeffcoat AR, et al. Sustained drug delivery systems II: Factors affecting release rates from poly(epsilon-caprolactone) and related biodegradable polyesters. J Pharm Sci. 1979;68(12):1534-1538. [42]Pitt CG, Schindler A. Capronor: A biodegradable delivery system for levonorgestrel. In: Zatuchni GI, Goldsmith A, Shelton JD, Sciarra JJ, edits. Long-Acting contraceptive delivery systems. Philadelphia: Harper and Row, 1984: 48-63.[43]Darney PD, Monroe SE, Klaisle CM, et al. Clinical evaluation of the Capronor contraceptive implant: preliminary report. Am J Obstet Gynecol. 1989;160(5 Pt 2):1292-1295.[44]Phase II--clinical trial with biodegradable subdermal contraceptive implant Capronor (4.0-cm single implant). Indian Council of Medical Research Task Force on Hormonal Contraception. Contraception. 1991;44(4):409-417.[45]Darney PD, Klaisle CM, Monroe SE, et al. Evaluation of a 1-year levonorgestrel-releasing contraceptive implant: side effects, release rates, and biodegradability. Fertil Steril. 1992; 58(1):137-143.[46]Ma G, Song C, Sun H, et al. A biodegradable levonorgestrel-releasing implant made of PCL/F68 compound as tested in rats and dogs. Contraception. 2006;74(2):141-147.[47]施化莲,孙洪范,武莉. 可降解长效抗生育埋植剂(Capro-F)的大白鼠抗生育作用[J]. 中国计划生育杂志, 1998(6): 254-255.[48]王彭延,宋存先,施化莲,等. 可降解长效抗生育埋植剂的研究[J]. 生物医学工程与临床, 1997(1): 23-26.[49]宋存先,杨菁,孙洪范,等. 左炔诺孕酮长效缓释埋植剂 I. 结构特征的研究和体内外药物释放的长期观察[J]. 中国生物医学工程学报,1999,18(1):22-29.[50]Wang PY, Song CX, Sun HF, et al. A biodegradable long-term contraceptive implant developed in China. Proceedings of the 20th Annual International Conference of the ZEEE Engineering in Medicine and Biology Society. 1998; 20(6): 2901-2904.[51]唐丽娜,孙洪范,宋存先,等. 长效抗生育埋植剂CaproF体内药物释放的研究[J]. 生物医学工程与临床, 2007,11(1): 17-19．[52]刘春海, 钱丽娟. 可生物降解皮下埋植剂CaproF的临床初步研究[J].中国计划生育杂志, 2000(3): 108-111.[53]王彭延, 存先,施化莲,等. 可降解长效抗生育埋植剂及I期临床结果[C].21世纪医学工程学术研讨会论文摘要汇编, 2001:58.[54]Song CX, Chen HY, Feng XD. Preparation of block coplymer of ε-caprolactone and DL-lactide and their evaluation as carrier for biodegradable sustained drug delivery. Acta Polymerica Sinica. 1983; 1(3): 177-183.[55]顾忠伟,杨纪元,杜福胜,等. 生物降解左旋-18甲长效避孕埋植剂的研制及其体外释放研究[J]. 中国计划生育学杂志,1997(2): 70-73．[56]顾忠伟,丁训诚,杨纪元,等. 生物降解左旋-18基长效避孕埋植剂载体材料的生物相容性研究[J]. 中国计划生育学杂志, 1997(3): 135-141.[57]王英,顾忠伟,王红,等. 左旋-18甲基炔诺酮生物降解长效避孕埋植剂抗生育作用的研究[J]. 中国计划生育学杂志,1999(1): 11-13.[58]Heller J, Penhale DW, Fritzinger BK, et al. Controlled release of contraceptive steroids from biodegradable poly (ortho esters). Contracept Deliv Syst. 1983;4(1):43-53.[59]Gresser JD, Wise DL, Beck LR, et al. Biodegradable cylindrical implants for fertility regulation. In: Hafez ES, Van Os WA, edits, Biodegradables and delivery systems for contraception. Boston, Massachusetts: G.K. Hall Publishers, 1980: 83-95.[60]李坤, 刘晓君，陈庆华, 等. 可生物降解长效注射给药系统的研究进展[J]. 中国医药工业杂志,2012,43(3):214-221.[61]Gentile P, Chiono V, Carmagnola I, et al. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci. 2014;15(3):3640-3659. [62]Sachlos E, Czernuszka JT. Making tissue engineering scaffolds work. Review: the application of solid freeform fabrication technology to the production of tissue engineering scaffolds. Eur Cell Mater. 2003;5:29-39.[63]Karp JM, Shoichet MS, Davies JE. Bone formation on two-dimensional poly(DL-lactide-co-glycolide) (PLGA) films and three-dimensional PLGA tissue engineering scaffolds in vitro. J Biomed Mater Res A. 2003;64(2):388-396.[64]Yang L, Li J, Li M, et al. The in vitro and in vivo degradation of cross-linked poly(trimethylene carbonate)-based networks. Polymers. 2016; 8 (4): 151. [65]Yang L, Li J, Zhang W,et al. The degradation of poly(trimethylene carbonate) implants: the role of molecular weight and enzymes. Polymer Degradation and Stability. 2015; 122: 77-87. [66]Yang L, Li J, Jin Y, et al. In vitro enzymatic degradation of the cross-linked poly(ε-caprolactone) implants. Polymer Degradation and Stability. 2015; 112: 10-19.[67]Yang L, Li J, Jin Y, et al. Highly efficient cross-Linking of poly(trimethylene carbonate) via bis(trimethylene carbonate) or bis(ε-caprolactone). Polymer. 2014; 55(26): 6686-6695. [68]Yang L, Li J, Meng S, et al. The in vitro and in vivo degradation behavior of poly (trimethylene carbonate-co-ε-caprolactone) implants. Polymer. 2014; 55(20): 5111-5124. [69]Yang L, He B, Meng S, et al. Biodegradable cross-linked poly(trimethylene carbonate) networks for implant applications: synthesis and properties. Polymer. 2013; 54(11): 2668-2675.[70]Yang LQ, Yang D, Guan YM, et al. Random copolymers based on trimethylene carbonate and ε-caprolactone for implant applications: synthesis and properties. Journal of Applied Polymer Science. 2012; 124(5): 3714-3720. |
.jpg)
.jpg)